에 대한 최신 뉴스 Defiance Quantum ETF (NASDAQ:QTUM)

Technology

Industrials

Communication Services

Other

Basic Materials

Consumer Cyclical

 The Fund uses a passive management (or indexing) approach to track the total return performance, before fees and expenses, of the Index, The Fund will generally use a replication strategy to achieve its investment objective, meaning the Fund will generally invest in all of the component securities of the Index in the same approximate proportions as in the Index. However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return, and other characteristics closely resemble the risk, return, and other characteristics of the Index as a whole, when the Funds sub-adviser believes it is in the best interests of the Fund (e.g., when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable, or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index)., The Fund generally may invest in securities or other investments not included in the Index, but which the Funds sub-adviser believes will help the Fund track the Index. For example, the Fund may invest in securities that are not components of the Index to reflect various corporate actions and other changes to the Index (such as reconstitutions, additions, and deletions).

Lockheed Martin Corp

Northrop Grumman Corp.

Accenture Plc

International Business Machines Corp.

Orange Sa Adr

Raytheon Co.

Nippon Telegraph & Telephone Corp

Juniper Networks Inc.

Koninklijke Kpn Nv

Wipro Ltd. Adr

Defiance Quantum ETF

Equities

Markets

Movers

General

IONQ

NVDA

QBTS

QTUM

QUBT

RGTI

TMAT

양자 컴퓨팅 관련 주식들이 산업 발전, 주요 파트너십 그리고 투자자들의 높은 열기에 힘입어 큰 폭으로 상승하고 있다. 약물 발견, 암호화 및 인공지능(AI) 등 다양한 분야에서의 잠재력으로 인해 이 신흥 기술 분야가 주목받고 있으며, 양자 컴퓨팅은 투자자들에게 주요 관심사로 자리잡고 있다.

양자 컴퓨팅 주식 개요: D-웨이브, 리제티, 아이온큐가 폭발적인 성장으로 선두

Quantum - United States dollar

Macquarie analyst Tao Qiu initiates coverage on Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Outperform rating and announces Price Target of $25.

News

Price Target

Initiation

Analyst Ratings

PRVA

Macquarie Initiates Coverage On Privia Health Gr with Outperform Rating, Announces Price Target of $25

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $490 to $494. Stifel analyst Paul Matteis maintained a Hold rating. Vertex Pharmaceuticals shares closed at $463.73 on Friday. See how other analysts view this stock.</li>
<li>Jefferies raised the price target for Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) from $63 to $70. Jefferies analyst Akash Tewari upgraded the stock from Hold to Buy. Bristol-Myers Squibb shares closed at $55.78 on Friday. <a href="https://www.benzinga.com/quote/BMY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer boosted the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $825 to $1,065. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Netflix shares closed at $918.87 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut MKS Instruments, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) price target from $155 to $150. Morgan Stanley analyst Joseph Moore maintained an Overweight rating. MKS Instruments shares settled at $112.55 on Friday. <a href="https://www.benzinga.com/quote/MKSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital raised RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $320 to $450. Loop Capital analyst Anthony Chukumba maintained a Hold rating. Walmart shares closed at $446.04 on Friday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $92 to $82. Deutsche Bank analyst Krisztina Katai maintained a Buy rating. NIKE shares closed at $77.25 on Friday.  <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $122 to $135. Rosenblatt analyst Barton Crockett maintained a Buy rating. Disney shares closed at $113.34 on Friday. See how other analysts view this stock.</li>
<li>Mizuho cut the price target for Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) from $137 to $134. Mizuho analyst Nitin Kumar maintained a Neutral rating. Exxon Mobil shares settled at $110.84 on Friday. <a href="https://www.benzinga.com/quote/XOM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised CNX Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNX#NYSE">CNX</a>) price target from $33 to $38. Mizuho analyst Nitin Kumar downgraded the stock from Neutral to Underperform. CNX Resources shares closed at $37.79 on Friday. <a href="https://www.benzinga.com/quote/CNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush raised Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $400 to $515. Wedbush analyst Daniel Ives maintained an Outperform rating. Tesla shares closed at $436.23 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png" alt="" class="wp-image-693891" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-1024x483.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16083522/image-126.png 1176w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

MKSI

NFLX

TSLA

VRTX

Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday

- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin
- Annualized height velocity was similar at Week 26 in once-weekly TransCon hGH-treated and daily somatropin-treated children
COPENHAGEN, Denmark, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced positive Week 26 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. to investigate the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; approved for pediatric growth hormone deficiency) compared to daily somatropin in prepubertal children with Turner syndrome.
New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old into one of four treatment groups 1:1:1:1 – one of three starting doses of TransCon hGH (0.24, 0.30, or 0.36 mg/kg/week) or an active comparator of daily somatropin with a starting dose of 0.35 mg/kg/week. Doses were individualized based on IGF-1.
<ul>
<li>On the primary endpoint of annualized height velocity and secondary endpoint of change from baseline in height SDS, children treated with TransCon hGH demonstrated improved growth similar to daily somatropin at Week 26, independent of starting dose.
<ul>
<li>In the trial, TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily somatropin.</li>
</ul>
</li>
</ul>

Biotech

ASND

Ascendis Pharma Presents New InsiGHTS Trial Of TransCon hGH In Turner Syndrome Achieved Primary Objective At Week 26; Results For All Three TransCon hGH Starting Dose Cohorts, In First Clinical Trial Of An Indication Outside Of Growth Hormone Deficiency, Showed A Safety And Tolerability Profile Comparable To Daily Somatropin

Macquarie analyst Tao Qiu initiates coverage on Healthcare Services Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCSG#NASDAQ">HCSG</a>) with a Neutral rating and announces Price Target of $13.

HCSG

Macquarie Initiates Coverage On Healthcare Services Group with Neutral Rating, Announces Price Target of $13

CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement.

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

Cardio Diagnostics Holdings Receives Final Medicare Pricing Determination From Centers For Medicare And Medicaid Services

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>, IINNW))), ("Inspira Technologies," "Inspira" or the "Company"),&nbsp;a groundbreaking respiratory support technology company, announced the delivery of INSPIRA&#x2122;&nbsp;ART100&nbsp;systems to its U.S. distributor, Glo-Med Networks Inc ("Glo-Med"). The systems were shipped in fulfilment of a purchase order issued by Glo-Med to Inspira.

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies Announces The Delivery Of INSPIRA ART100 Systems To Its U.S. Distributor, Glo-Med Networks

Macquarie analyst Tao Qiu initiates coverage on Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Outperform rating and announces Price Target of $18.

Macquarie Initiates Coverage On Pediatrix Medical Group with Outperform Rating, Announces Price Target of $18

WIIM

PLBY

PLBY Group shares are trading higher after the company announced it expanded its relationship with Byborg Enterprises where Byborg will commit to a buy minimum of $25 million of additional equity.

BEAT

HeartBeam shares are trading higher after the FDA granted the company 510(k) clearance of its system for comprehensive arrhythmia assessment.

HeartBeam Announced FDA Clearance For Its HeartBeam System For Comprehensive Arrhythmia Assessment

<ul>
<li>Combination increases scale with $24 billion in assets, 148 branch offices and a longstanding history of serving clients and communities</li>
<li>Highly compatible cultures, deep community ties and operating philosophies&nbsp;</li>
<li>0.42 Berkshire shares for each Brookline share; Berkshire's dividend expected to be increased to have a neutral impact on Brookline shareholders</li>
</ul>
BOSTON, Dec. 16, 2024 /PRNewswire/ -- Berkshire Hills Bancorp, Inc. ("Berkshire") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHLB#NYSE">BHLB</a>), the parent company of Berkshire Bank ("Berkshire Bank"), and Brookline Bancorp, Inc. ("Brookline") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKL#NASDAQ">BRKL</a>), the parent company of Brookline Bank, Bank Rhode Island, and PCSB Bank&nbsp;(the "Banks"), today announced they have entered into a definitive agreement pursuant to which Brookline will merge with and into Berkshire in an all-stock transaction valued at approximately $1.1 billion, or $12.68 per share of Brookline common stock, based on the $30.20 closing price of Berkshire common stock on December 13, 2024.

BHLB

BRKL

Berkshire Hills Bancorp And Brookline Bancorp Announce A Merger Of Equals To Create A Premier Northeast Banking Franchise; Brookline Will Merge With And Into Berkshire In An All-Stock Transaction Valued At ~$1.1B, Or $12.68 Per Share Of Brookline Common Stock

NMHI

Nature's Miracle Holding shares are trading higher after the company announced it will acquire a 90% equity interest in J&Y Marigold.

Lake Street analyst Ryan Meyers initiates coverage on a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Buy rating and announces Price Target of $30.

Lake Street Initiates Coverage On a.k.a. Brands Holding with Buy Rating, Announces Price Target of $30

Nature's Miracle Holding To Acquire Controlling Stake In J&Y Marigold, Bolstering Bitcoin Mining Capabilities; To Purchase 90% Share For $5.32M

Management

ENVX

Enovix Corporation Announced Its CFO Farhan Ahmad Has Left The Company And That It Is Searching For A New CFO

Loop Capital analyst Rob Sanderson maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $385 to $450.

Loop Capital Maintains Buy on AppLovin, Raises Price Target to $450

As Part of a Procedural Measure due to a Timing Requirement from Nasdaq, Trading is Expected to Temporarily Transition to OTC Markets and, Upon Consummation of the Business Combination, will Relist on Nasdaq
FTAC Emerald Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLD#NASDAQ">FLD</a>) ("FTAC Emerald"), a publicly-traded special purpose acquisition company, today announced that it will change its ticker symbol for its Common Stock. Beginning on December 18, 2024, FTAC Emerald's Common Stock will begin trading under the new ticker symbol FLDD. FTAC Emerald's Units and Warrants will continue to trade under the symbols FLDDU, and FLDDW, respectively.
As anticipated as a procedural measure due to a timing requirement by Nasdaq, FTAC Emerald's common stock, units, and warrants are expected to transition from Nasdaq to OTC Markets. The new ticker symbol will ensure uninterrupted market activity for shareholders. FTAC Emerald's ongoing business combination agreement with Fold, a pioneering bitcoin financial services company, will be unaffected by the transition of trading venue.

FTAC Emerald Acquisition Corp. Announces Change Of Ticker Symbol Of Its Common Stock To "FLDD" Commencing December 18, 2024

Contracts

SAIC

Science Applications Internationnal Wins Prime Position On $1.B Personal And Readiness Infrastructure Support Management Award Task Order Contract

On Monday, Danish pharmaceutical firm Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced plans to invest approximately $1.20 billion (8.5 billion Danish kroner) to establish a new production facility in Odense, Denmark.
The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site. The new site will <a target="_blank" href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915079" rel="noreferrer noopener">feature</a> a finished production facility and warehouse of over 40,000 m2.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42489755/novo-nordisks-ozempic-potentially-linked-to-rare-vision-loss-risk-but-study-concludes-absolute-increase-in-risk-minimal" rel="noreferrer noopener">Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study</a>
Designed to be modular and flexible, it will accommodate multiple product types within rare diseases, such as hemophilia. Construction work has commenced and is scheduled to be completed in 2027.
The investment is expected to create 400 permanent jobs upon completion of the facilities. Up to 1,000 external employees will be working on-site during the construction process.
On Friday, Novo Holdings announced it had <a target="_blank" href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915078" rel="noreferrer noopener">fulfilled</a> all regulatory requirements to finalize its acquisition of Catalent Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>).
The closure comes amid a coalition of unions, consumer groups, and public interest organizations voicing strong opposition to&nbsp;Novo Holdings'&nbsp;proposed&nbsp;$16.5 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41409503/after-us-senator-unions-urge-federal-trade-commission-to-block-novos-16-5b-acquisition-of-catalen" rel="noreferrer noopener">acquisition&nbsp;of&nbsp;Catalent</a>.
Last week, the European Commission <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915074" rel="noreferrer noopener">approved</a> Novo Holdings' acquisition of Catalent and Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings.
The deal for the three sites is expected to close in the coming days. Once completed, the acquisition will affect Novo Nordisk's financial outlook, including:
2024 Impact: A slight negative effect on operating profit growth and a reduction in free cash flow by $11.7 billion, the acquisition's cost. The ongoing 20 billion Danish krone share buyback program remains unaffected.
2025 Impact: Operating profit growth is projected to face a moderate negative impact, with interest payments from debt financing affecting net financial items. Novo Nordisk does not plan to launch a share buyback program in 2025.
Price Action: At last check on Monday, NVO stock was up 0.93% at $107.94 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42490115/despite-higher-valuations-some-life-sciences-tools-stocks-create-good-opportunities-analyst" target="_blank" rel="noreferrer noopener">Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

CTLT

Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent

Comments

Defiance Quantum ETF

뉴스

에 대한 최신 뉴스 Defiance Quantum ETF (NASDAQ:QTUM)

일요일, 12월 08, 2024

뉴스

파트너 / 기고자

벤징가 글로벌